Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial. Long-term treatment outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results